What this trial studies
Radicle Revive™: A randomized, double-blind, placebo-controlled study assessing the impact of health and wellness products on menopausal-related health issues associated health outcomes.
Conditions in scope
- Cognitive Function
Interventions
- Revive Product Placebo Control (Dietary Supplement) — Participants will use their Control as directed for a period of 12 weeks.
- Revive Active Product 1 (Dietary Supplement) — Participants will use their Active product as directed for a period of 12 weeks.
Who can join
Women only · Ages 40 Years to 105 Years · Accepts healthy volunteers.
Inclusion criteria
- Inclusion
- Participants must meet all the following criteria:
- Adults, at least 40 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities
- Assigned sex at birth will determine sex-specific recruitment
- Resides in the United States
- Has the opportunity for at least 30% improvement in their primary health outcome
- Peri or Post Menopausal women who have been experiencing hot flashes for the past 3 months or longer
- Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study
Exclusion criteria
- See ClinicalTrials.gov for full exclusion criteria.
Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.
Where it’s happening
| City | State / Region | Facility | Site status |
|---|---|---|---|
| Del Mar | California | Radicle Science Inc. | Recruiting |
Status & timeline
- Overall status: Recruiting
- Study type: Interventional
- Phase: N/A
- Start date: 2026-04-09
- Primary completion: 2027-04-07
- Last update posted: 2026-04-23
- First posted: 2026-04-23
Sponsor & contact
Lead sponsor: Radicle Science (Industry)
For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.
Outcome measures
Primary outcomes
- Change in cognitive function (13 weeks)
Change in cognitive function: Difference in rates of change over time in cognitive function score as assessed by PROMIS Cognitive Function 8A (scale 8-40; where lower scores correspond to worse cognitive function)
Related ClearedRx care
If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.
Important. Information from ClinicalTrials.gov as of May 8, 2026. Trial details (status, sites, contacts, eligibility, outcomes) change frequently — always check the official record at https://clinicaltrials.gov/study/NCT07548307 before contacting a site.
ClearedRx is not affiliated with this trial or its sponsor. We index public-domain ClinicalTrials.gov records to help patients find evidence-based context for menopause care decisions. ClearedRx itself is a telehealth menopause/HRT brand — we do not enroll patients in trials.